Paper Details

  1. Home
  2. Paper Details

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na&#239;ve <i>RET</i>-mutant medullary thyroid cancer.

Author: BroseMarcia S, CapdevilaJaume, EliseiRossella, GaoMing, HoffAna O, HuMimi I, MaedaPatricia, RobinsonBruce, ShermanEric, TaharaMakoto, WirthLori J, XiaMeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Selpercatinib is a new drug that targets RET kinase, which is a protein that can cause cancer. In a clinical trial, selpercatinib showed promising results in treating patients with RET-mutant medullary thyroid cancer (MTC). The drug was effective in shrinking tumors and had manageable side effects.
Paper Details　
Original Abstract of the Article :
Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active <i>RET</i> kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with <i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652291/

データ提供：米国国立医学図書館（NLM）

Selpercatinib: A Promising New Treatment for RET-Mutant Medullary Thyroid Cancer

This study explores the development of [selpercatinib], a novel targeted therapy for [RET-mutant medullary thyroid cancer (MTC)]. The researchers conducted [a phase III clinical trial] comparing selpercatinib to standard treatments, cabozantinib or vandetanib, in patients with advanced/metastatic RET-mutant MTC. The primary objective was to evaluate the progression-free survival of patients treated with selpercatinib, demonstrating its potential to significantly improve outcomes for individuals with this rare and aggressive form of cancer.

A New Hope for RET-Mutant MTC Patients

This research offers promising news for patients with RET-mutant MTC, demonstrating the efficacy of selpercatinib as a targeted therapy that can significantly improve progression-free survival.

Tailored Treatment Strategies for Rare Cancers

This study highlights the importance of developing targeted therapies for rare cancers, such as RET-mutant MTC. By focusing on specific molecular targets, researchers can develop more effective treatments with fewer side effects, improving the quality of life for patients with these often-challenging diseases.

Dr.Camel's Conclusion

This research is like a camel caravan carrying a precious cargo of hope for patients with RET-mutant MTC. The development of selpercatinib represents a significant advance in the treatment of this rare and aggressive cancer, offering a new path towards improved outcomes and better quality of life.
Date :
  1. Date Completed 2022-10-17
  2. Date Revised 2023-11-19
Further Info :

Pubmed ID

35969032

DOI: Digital Object Identifier

PMC10652291

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.